Dementia Matters7 Okt 2025

Clarifying the Alzheimer’s Disease Clinical Trials Landscape

Clinical trials are essential for improving the lives of those diagnosed with Alzheimer’s disease and related dementias. With so many trials out there, it can be difficult for someone who’s interested in participating in research to know where to start. Dr. Jonathan Graff-Radford joins the podcast to discuss the ins and outs of clinical trials and the state of Alzheimer’s treatments today, as well as share some highlights from his presentation at the National Alzheimer’s Coordinating Center’s (NACC) 2025 Spring ADRC Meeting.

Guest: Jonathan Graff-Radford, MD, behavioral neurologist, associate professor, vice chair, Mayo Clinic Department of Neurology, co-investigator, Mayo Clinic Alzheimer’s Disease Research Center

Show Notes

Read more about Dr. Jonathan Graff-Radford at his profile on Mayo Clinic’s website.

Listen to part one and part two of our series on preclinical Alzheimer’s disease and the AHEAD study with Dr. Reisa Sperling, mentioned at 19:53, on our website.

Learn more about the AHEAD study on their website.

Learn more about clinical trials in Wisconsin at the UW Clinical Trials Institute's website.

Interested in participating in clinical trials? Visit clinicaltrials.gov or Alzheimer's Association's TrialMatch to learn how to get involved.

Learn more and register for the 2025 Fall Community Conversation: Addressing Hearing Loss for Better Brain Health on our website.

Connect with us

Find transcripts and more at our website.

Email Dementia Matters: dementiamatters@medicine.wisc.edu

Subscribe to the Wisconsin Alzheimer’s Disease Research Center’s e-newsletter.

Enjoy Dementia Matters? Consider making a gift to the Dementia Matters fund through the UW Initiative to End Alzheimer’s. All donations go toward outreach and production.

Det här avsnittet är hämtat från ett öppet RSS-flöde och publiceras inte av Podme. Det kan innehålla reklam.

Avsnitt(244)

New Alzheimer’s Association Special Report Breaks Down How Americans Understand and Support their Brain Health

In recent years, public interest in brain health has increased. So how are Americans understanding brain health information and incorporating it into their own lives? This year, the Alzheimer’s Associ...

25 Aug 37min

Reflecting on 25 Years of the Wisconsin Registry for Alzheimer’s Prevention

Twenty-five years ago, a single participant enrolled in what would become the Wisconsin Registry for Alzheimer's Prevention (WRAP), now one of the largest and longest-running studies of Alzheimer's ri...

12 Aug 35min

How Dementia Caregiving Affects the Spousal Caregiver

Caring for those with dementia represents a major public health challenge, with caregivers, especially spouses, providing long-term, largely unpaid care. With caregiving stress linked to a decline in ...

28 Juli 39min

Managing the Medicine Cabinet: How Prescriptions Impact Cognition and Brain Health as We Age

Prescription medications, over-the-counter drugs and supplements are incredibly common among older adults, yet many of these routine treatments can unexpectedly impact cognitive function and brain hea...

14 Juli 35min

Taking a Deep Dive into Subjective Cognitive Decline

Dr. Jessen returns to the podcast to take a deeper dive into subjective cognitive decline (SCD). Aiming to cover everything relating to SCD, Dr. Jessen shares insights in prognosis, risk factors and h...

7 Juli 17min

Defining Subjective Cognitive Decline

Subjective cognitive decline (SCD) can be one of the earliest noticeable signs of Alzheimer's disease, yet SCD is not yet fully understood. To help us understand more, Dr. Frank Jessen, an expert in t...

30 Juni 30min

SPRINT to a Healthy Mind: How Blood Pressure Control Affects Brain Health and Dementia Risk

Geriatrician Dr. Mark Supiano joins the podcast to discuss the connection between heart and brain health. Citing multiple clinical trials, he breaks down what these studies and their findings mean for...

18 Juni 40min

Addressing Cochrane’s Review on Amyloid-Targeting Treatments for Alzheimer’s Disease

Amyloid-targeting monoclonal antibody treatments have ushered in a new era of Alzheimer’s disease therapies after decades of research and clinical trials. A recent review published by Cochrane, a glob...

4 Juni 44min